Clinical trial NCT03956654: A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With Breastcancer
Official title: A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib With Letrozole in Older Women (≥70 Years) With HR+ and HER2- Advanced Breast Cancer (aBC) With no Prior Systemic Therapy for Advanced Disease.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Breast Cancer
Keywords: breast cancer
elderly
geriatric assessment
geriatric oncology
translational research
biomarkers
Lead sponsor: Universitaire Ziekenhuizen KU Leuven
Sponsor class: OTHER
First posted: 2019-05-21
Enrollment: 78
Sex: FEMALE
Minimum age (years): 70
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This study will include older women (defined as ≥70 years) with HR+, HER2- advanced breast cancer who had not received any prior hormonal agent for treatment of advanced disease. It is expected that at least 50% of patients will be older than 75 years.

Brief summary: The RibOB study is a prospective, open lable, single arm trial which will evaluate the clinical efficacy, overall safety and tolerability of ribociclib in combination with letrozole in older women (≥70 years) with HR+/HER2- aBC and no prior hormonal treatment for advanced disease (as per approved indication).

Detailed description: The RibOB study is an observational prospective, open lable single arm phase IV trial which will evaluate the clinical efficacy, overall safety and tolerability of ribociclib in combination with letrozole in older women (≥70 years) with HR+, HER2- advanced breast cancer and no prior hormonal treatment for advanced disease as per the indication approved by the European Medicines Authority (EMA) and as made available by Belgian national authorities in the national health care system. A total of maximum 150 patients will be enrolled for treatment with Letrozole (2.5 mg once daily) + ribociclib 600 mg (day 1 to 21 in a 28 day cycle), which will continue until disease progression, intolerable toxicity or patient/physician decision to withdraw. During the study, patients will be continuously evaluated for disease progression as per national standard of care (approximately every 12 weeks radiologically); for safety; and for quality of life and geriatric assessment components including functional status with QoL assessment and CGA at 3 months (+/- 2 weeks) and at 1 year (+/-2 weeks).

Eligibility criteria: Inclusion Criteria:

* Patient is a female ≥ 70 years old at the time of informed consent.
* Advanced breast cancer (defined as locoregionally recurrent or metastatic not amenable to curative therapy).
* Histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer by local laboratory (defined as ER and/or PgR ≥1% or Allred \>2).
* HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test as determined by local laboratory testing according to ASCO-CAP guidelines is necessary.
* Patient has adequate bone marrow and organ function as defined by the following laboratory values (as assessed by local laboratory), preferably tested a maximum of 14 days before enrolment:
* Patient has signed informed consent obtained before any trial-related activities and according to local guidelines.
* Subjects must be able to communicate with the investigator and comply with the requirements of the study procedures.

Exclusion Criteria:

* Patient has a known hypersensitivity to any of the excipients of ribociclib or letrozole.
* Patients who received any CDK4/6 inhibitor previously.
* Patient who received any prior systemic antihormonal therapy or chemotherapy for advanced breast cancer.
* Patient is concurrently using other systemic anti-cancer therapy (except bone modifying agents).
* Patient with central nervous system (CNS) metastases and/or documented meningeal carcinomatosis unless they meet ALL the following criteria:
* At least 4 weeks from prior therapy for CNS disease completion (including radiation and/or surgery) to starting the study treatment;
* Clinically stable CNS lesions at the time of study treatment initiation and not receiving steroids and/or enzyme-inducing anti-epileptic medications for the management of brain metastases for at least 2 weeks (radiological confirmation of brain disease status is not necessary).
* Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol: (e.g. chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.).
* Patients who already have or who are at significant risk of developing QTc prolongation are not eligible for the study. This includes patients:
* with long QT syndrome;
* with uncontrolled or significant cardiac disease, including recent myocardial infarction, congestive heart failure, unstable angina and bradyarrhythmias;
* with electrolyte abnormalities (potassium, magnesium, sodium and calcium) that are NCI CTCAE 4.03 grade 2 or higher (for details, see table 10 ). Note: phosphate testing is not mandatory, but should the investigator consider measuring it before enrolment, the same rules may be applied

Primary outcomes:
measure: Progression-free survival (PFS)
timeFrame: 2018-2022
Secondary outcomes:
measure: Time to treatment failure (TTF)
timeFrame: 2018-2022
measure: Overall response rate (ORR)
timeFrame: 2018-2022
measure: Overall Survival (OS)
timeFrame: 2018-2022
measure: Breast cancer specific survival (BCSS)
timeFrame: 2018-2022
measure: Adverse events
timeFrame: 2018-2022
measure: Treatment discontinuation
timeFrame: 2018-2022
measure: Treatment interruption
timeFrame: 2018-2022
measure: Treatment reduction
timeFrame: 2018-2022
measure: PFS / OS
timeFrame: 2018-2022
measure: CGA / QoL
timeFrame: 2018-2022
measure: Quality of Life (1)
timeFrame: 2018-2022
measure: Quality of Life (2)
timeFrame: 2018-2022
measure: Quality of Life (3)
timeFrame: 2018-2022
measure: Comprehensive Geriatric Assessment
timeFrame: 2018-2022
measure: Plasma Biomarker Research (1)
timeFrame: 2018-2022
measure: Plasma Biomarker Research (2)
timeFrame: 2018-2022
measure: Plasma Biomarker Research (3)
timeFrame: 2018-2022
measure: Plasma Biomarker Research (4)
timeFrame: 2018-2022
Other outcomes:
Locations:
city: Leuven
country: Belgium
facility: UZ Gasthuisberg Leuven
Study officials:
affiliation: UZ Gasthuisberg
name: Hans Wildiers, prof. dr.
role: STUDY_CHAIR
References: